Pharmacological in vitro characterization of the arecoline bioisostere, Lu 25-109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties

Drug Development Research

Volumn 40, Issue 1, 1997, Pages 1-16

  Meier, Eddi ^a   Frederiksen, Kristen ^a   Nielsen, Mogens ^b   Lembøl, Hanne Løve ^a   Pedersen, Henrik ^a   Hyttel, John ^a  

^a H LUNDBECK A S   (Denmark)

^b Sct Hans Hospital   (Denmark)

Author keywords

Alzheimer's disease; Arecoline bioisostere; Lu 25 109 T; Muscarinic receptor subtypes; R586; Xanomeline

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ARECOLINE; ATROPINE; CARBACHOL; MUSCARINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; OTENZEPAD; OXOTREMORINE; PIRENZEPINE; QUINUCLIDINYL BENZILATE; XANOMELINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN STEM; CELL CULTURE; CHO CELL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GENE EXPRESSION; GRANULAR CELL; GUINEA PIG; HEART LEFT ATRIUM; HUMAN; ILEUM; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SALIVARY GLAND; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERIOR CERVICAL GANGLION;

EID: 0030998289     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199701)40:1<1::AID-DDR1>3.0.CO;2-Q     Document Type: Article

References (85)

1. Arendt T, Allen Y, Marchbanks RM, Schugens MM, Sinden J, Lantos PL, Gray JA (1989): Cholinergic system and memory in the rat: Effects of chronic ethanol, embryonic basal forebrain brain transplants and excitotoxic lesions of cholinergic basal forebrain projection system. Neuroscience 33:435-462.
2. Arnt J, Lemboøl HL, Meier E, Pedersen H (1992): Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and O-Me-THPO in rats: Evidence for involvement of different muscarinic receptor subtypes. Eur J Pharmacol 218:159-169.
3. 2 receptor binding sites are increased in certain cortical brain regions of aged memory-impaired as compared tomemory-unimpaired rats. Life Sci 52:591.
4. Beller SA, Overall JE, Swann AC (1987): Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology 87:147-151.
5. Birdsall NJM, Hulme EC (1983): Muscarinic receptor subclasses. TIPS 4:459-463.
6. 3H]N-methyl-carbamylcholine, a new radioligand specific for nicotinic acetylcholine receptors in brain. Eur J Pharmacol 139:323-333.
7. 1 agonist: Clinical study in mild and moderate Alzheimer's disease. Oral presentation at the 6th Int. Symp. on subtypes of muscarinic receptors. Fort Lauderdale, FL November 1994.
8. Brown DA, Farherazi J, Garthwaite J, White RD (1980): Muscarinic receptors in rat sympathetic ganglia. Br J Pharmacol 70:577-592.
9. Brunner F, Wailbroeck M, Christophe J (1986): Secoverine is a non-selective muscarinic antagonist on rat heart and brain receptors. Eur J Pharmacol 127:17-25.
10. Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989): Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35:469-476.
11. 1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J Med Chem 38:4380-4392.
12. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
13. Collerton D (1986): Cholinergic functions and intellectual decline in Alzheimer's disease. Neuroscience 19:1-28.
14. Consolo S, Wu CF, Fiorentini F, Ladinsky H, Vezzani A (1987): Determination of endogenous acetylcholine release in freely moving rats by transstriatal dialysis coupled to a radioenzymatic assay: Effect of drugs. J Neurochem 48:1459-1465.
15. Coyle JT, Price DL, DeLong MR (1983): Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 216:1184-1191.
16. 3H] (+)-pentazocine to σ recognition sites in Guinea Pig Brain. Eur J Pharmacol 227:371-378.
17. Dekker AJAM, Connor DJ, Thal LJ (1991): The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 15:299-317.
18. DeLapp NW, Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS (1995): The M1 agonist xanomeline potently stimulates APPs release from CHO-M1 cells. Life Sci 56:1024 (abstract 45).
19. 2 antagonists: Novel structures and pharmacology: Life Sci 52:497-503.
20. Domeney A, Arnt J, Costall B, Naylor RJ, Sánchez C, Smith (1994): Effect of sertindole on raised mesolinibic dopaminergic activity in the rat. Drug Dev Res 31:175-185.
21. Dörje F, Levey AI, Brann MR (1991): Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues. Mol Pharmacol 40:459-462.
22. Dunnet SB, Wareham AT, Torres EM (1990): Cholinergic blockade in prefrontal cortex and hippocampus disrupts short-term memory in rats. Neuro Rep 1:61-64.
23. Eagger S, Morant NJ, Levy R (1991): Parallel group analysis of the effects of tacrine versus placebo in Alzheimer's disease. Dementia 2:207-211.
24. Eagger S, Morant NJ, Levy R, Shakian B (1992): Tacrine in Alzheimer's disease. Time course of changes in cognitve function and practice effects. Br J Psychiatry 160:36-40.
25. El-Defrawy SR, Coloma F, Jhamandas K, Boegman RJ, Beninger RJ, Wirsching BA (1985): Functional and neurochemical cortical cholinergic impairment following neurotoxic lesions of the nucleus basalis magnocellularis in the rat. Neurobiol Aging 6:325-330.
26. Etienne P, Robitaille Y, Wood P, Gauthier S, Nair NPV, Quirion R (1986): Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neurosci 19:1279-1291.
27. 2 receptor binding. Relationship with functional efficacy. Eur J Pharmacol 156:133-142.
28. Freedman SB, Harley EA, Iversen LL (1988b): Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: The NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br J Pharmacol 93:437-145.
29. Freedman SB, Harley EA, Patel S (1989): Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding. Eur J Pharmacol 174:253-260.
30. Freedman SB, Dawson GR, Iversen LL, Baker R, Hargreaves RJ (1993): The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduces side-effect profile in vivo. Life Sci 52:489-495.
31. Geula C, Mesulam MM (1989): Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neuroscience 33:469-481.
32. Giacobini E (1994): Therapy of Alzheimer's disease - Symptomatic or neuroprotective. Mol Neurobiol 9:115-118.
33. Gurwitz D, Haring R, Pinkas-Kramarski R (1995): NGF-dependent neurotrophic-like effects of AF102B, an M1 Muscarinic agonist, in PC 12M1 cells. NeuroReport 6:485-488.
34. 1 receptors in the brain. Life Sci 34:597-605.
35. Hofman A, Rocca WA, Brayne C, Breteler MMB, Clarke M, Cooper B, Copeland JRM, Dartigues JF Da Silva Droux A, Hagnell O, Heeren TJ, Engedal K, Jonker C, Lindesay J, Lobo A, Mann AH, Mölsä PK, Morgan K, O'Connor DW, Sulkava R, Kay DWK, Amaducci L (1991): The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int J Epidemiol 20:736-748.
36. 3H]-Rainate binding sites with different molecular target sizes in rat cortex. Neurosci Lett 65:47-52.
37. Honoré T, Nielsen M (1985): Complex structura of quisqualate-sensitive glutamate receptors in rat cortex. Neurosci Lett 54:27-32.
38. Hoss W, Messer Jr WS, Monsma Jr FJ, Miller MD, Ellerbrock BR, Scranton T, Ghodsi-Hovsepian S, Price MA, Balan S, Mazloum Z, Bohnett M (1990): Biochemical and behavioural evidence for muscarinic autoreceptors in the CNS. Brain Res 517:195-201.
39. Hyttel J (1982a): Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxanthen neuroleptics. In Kohsaka M, Shohmori T, Tsukada Y, Woodruff GN (eds): Advances in Dopamine Research: Advances in the Biosciences. Oxford: Pergamon Press Ltd., pp 147-152.
40. Hyttel J (1982b): Citalopram - Pharmacological profile of a specific serotonin-uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol Biol Psychiat 6:277-295.
41. 2 receptors in corpus striatum of rats. Pharmacol Toxicol 61:126-129.
42. 3H]SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions. J Neural Transm 68:171-189.
43. 2-receptor antagonist. Drug Dev Res 15:389-404.
44. Hyttel J, Larsen J-J (1985): Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J Neurochem 44:1615-1622.
45. Hyttel J, Overø KF, Arnt J (1984): Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacol 83:20-27.
46. Hyttel J (1986): Effect of prolonged treatment with neuroleptics on dopamine D-1 and D-2 receptor density in corpus striatum in mice. Acta Pharmacol Toxicol 59:387-391.
47. Jones Penelope SV, Heilman CJ, Brann MR (1991): Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 40:242-247.
48. Julius D, MacDermott AB, Axel R, Jessell T (1988): Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science 241:558-564.
49. Kan JP (1992): Current and future approaches to therapy of Alzheimer's disease. Eur J Med Chem 27:565-570.
50. Lapchak PA, Araujo DM, Hefti F (1993): Muscarinic receptor-mediated control of hippocampal brain-derived neurotrophic factor (BDNF) mRNA expression. Life Sci 52:585.
51. 5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52:441-448.
52. Marchbanks RM (1982): Biochemistry of Alzheimer's dementia. J Neurochem 39:9-15.
53. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117.
54. Meier E, Schousboe A (1982): Differences between GABA receptor binding to membranes from cerebellum during postnatal development and from cultured cerebellar granule cells. Dev Neurosci 5:546-553.
55. 2-selectivity of test compounds: (1) α-adrenoceptor antagonists. Eur J Pharmacol 129:49-55.
56. Moltzen EK, Pedersen H, Bøgesø KP, Meier E, Frederiksen K, Sánchez C, Lembøl HL (1994): Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity. J Med Chem 37:4085-4099.
57. Mori F, Chen-Ching L, Fusi F, Giacobinin E (1995): Cholinesterase inhibitors increase secretion of APPs in rat brian cortex. NeuroReport 6:633-636.
58. 2 receptors mediate different effects on synaptically evoked potentials of the rat superior cervical ganglion. Neurosci Lett 88:100-106.
59. Newberrry NR, Priestley T (1987): Pharmacological differences between two muscarinic responses of the rat superior cervical ganglion in vitro. Br J Pharmacol 92:817-826.
60. 35S]t-butylbicyclo-phosphorothionate binding sites reveals complicated molecular arrangements of the GABA/benzodiazepine receptor chloride channel complex. Biochem Pharmacol 34:3633-3642.
61. 3H]Diazepam specific binding to rat cortex in vitro is enhanced by oleic, arachidonic and docosahexenoic acid isolated from pig brain. Eur J Pharmacol 146:349-353.
62. Nitsch RM, Growdon JH (1994): Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem Pharmacol 47:1275-1284.
63. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992): Processing of Alzheimer amyloid precursor protein is regulated by muscarinic acetylcholine receptor activation. Society for Neuroscience 18, Part 1, 1993.
64. Okaichi H, Jarrard LE (1982): Scopolamine impairs performance of a place and cue task in rats. Behav Neural Biol 35:319-325.
65. 2 receptor antagonist AF-DX 116 improves memory. Brain Res 524:72-76.
66. Pieri L, Cumin PR, Hinzen DH (1989): Nosological and epidemiological aspects of Alzheimer's disease. DN&P 2:248-253.
67. Pike BR, Hamm RJ (submitted): Activating the post-traumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury.
68. Pike BR, Hamm RJ, Zhu JP, Philips LL, Temple MD, Buck DL (submitted): Lu 25-109-T, a novel partial niuscarinic M1 agonist, improves cognitive outcome and attenuates decreases in septal choline acetyltransferase immunoreactivity (ChAT-IR) after traumatic brain injury (TBI) in rats.
69. Sánchez C et al. (in preparation).
70. Sánchez C, Meier E (1993): Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice. Phannacol Toxicol 72:262-267.
71. Sánchez C (1993): Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav Pharmacol 4:269-277.
72. Schoenberg BS, Kokmen E, Okazaki H (1987): Alzheimer's disease and other dementing illnesses in a defined United States population: Incidence rates and clinical features. Ann Neurol 22:724-729.
73. Schwartz AS, Kohlstaedt EV (1986): Physostigmine effects in Alzheimer's disease: Relationship to dementia severity. Life Sci 38:1021-1028.
74. Skarsfeldt T (in preparation): Effect of Lu 25-109-T on spartial learning and memory in young and aged rats using a Water Maze task.
75. 3 receptors of acetylcholine release from guinea pig ileum as measured directly. Eur J Pharmacol 249:1-6.
76. Sutherland RJ, Whishaw IQ, Regehr JC (1982): Cholinergic receptor blockade impairs spatial localization by use of distal cues in the rat. J Comp Physiol Psychol 96:563-573.
77. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P (1986): Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. ProgNeuro-Psychol Biol 10:627-636.
78. 3H]-QNB in rat brain tissue. Life Sci 40:1981-1987.
79. 3H]N-0437 to calf caudate membranes. Eur J Pharmacol 134:211-219.
80. 3H]TCP: A new tool with high affinity for the PCP receptor in rat brain. Brain Res 280:194-197.
81. Wagstaff AJ, Mctavish D (1994): Tacrine - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 4:510-540.
82. 3H]tolyl)guanidine: A Selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83:8784-8788.
83. Whitehouse PJ, Price DL, Struble RC, Clark AW,Coyle JT, DeLong MR (1982): Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237-1239.
84. Whitehouse PJ, An KS (1987): Cholinergic receptors in aging and Alzheimer's disease. Biol Psychiatry 10:665-676.
85. 3 muscarinic cholinoceptors are linked to phosphoinositide metabolism in rat cerebellar granule cells. Eur J Pharmacol 206:181-189.